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ABSTRACT 
Human infection due to Chromobacterium violaceum is rare, even though the bacteria are ubiquitous in distribution. Without 
appropriate antimicrobial therapy, the consequences can be rapidly fatal if septicemia sets in. Both pigmented and 
nonpigmented varieties are equally virulent. Mortality rates are quite high despite treatment. The history of trauma and 
simultaneous exposure to water and soil should alert clinician about this entity. Fluoroquinolones and aminoglycosides show 
good sensitivity, whereas penicillin and early cephalosporins are poor therapeutic options. Treatment for an extended period 
beyond clinical cure is indispensable to prevent relapse. Combination of prompt diagnosis, optimal antimicrobial therapy, and 
adequate therapeutic duration for C. violaceum infection is the key for successful therapy. We present here two cases of C. 
violaceum infections with interesting presentations with a brief review of literature. 
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sual pathogens cause a vast array of infections 
that we come across every day. Rarely, some 
unusual microbes may be isolated found 
ubiquitously in our environment. They could be pathogens 
or contaminants in certain precarious clinical conditions. 
One among the many of such sort, Chromobacterium 
violaceum (C. violaceum) naturally resides in soil and 
stagnant water of tropical and subtropical regions as 
saprophytes [1,2]. Although it was first identified in 1881, 
its pathogenic potential was illustrated only in 1905 by PG 
Woolley from a fatal case of a buffalo in Philippines. 
Human case of infection caused by this pathogen was first 
established by JE Lessler from Malaysia in 1927 [2]. Since 
then less than 180 cases have been documented in 
literature till late 2017 in Asia, Africa, South America, 
Australia, and southeastern United States [3,4]. Most 
strains of C. violaceum synthesize a non-diffusible violet 
pigment called violacein. This pigment is ethanol and 
acetone-soluble and insoluble in water, chloroform, ether, 
and benzene [5].  
 
Infection by non-pigmented strains is equally fatal. The 
predominant portal of entry is through broken skin 
exposed to the organism through trauma, exposure to 
water and soil or both [2,3]. Though rarely implicated in 
human infections, infections caused by this bacterium can 
be fatal. Rapid progression to sepsis with metastatic 
abscesses and multidrug resistance are striking features of 
C. violaceum infections. Mortality rates are substantially 
high (~55–60%) despite treatment [3]. We report here a 
case series of C. violaceum infections with varied 
presentations from Port Blair, Andaman & Nicobar 
Islands. These are the first such reports from these remote 
islands. 
Case 1 
A 22-year-old male presented to the emergency room of 
the hospital with complaints of high persistent fever, 
severe headache, vomiting, severe pain and a small 
pustular lesion on the dorsal aspect of his right foot. He 
U 
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had a toxic appearance with marked prostration. On 
admission, he was febrile with a temperature of 102˚F, 
continuous in character, pulse rate of 106 beats/min, blood 
pressure of 130/86 mmHg, respiratory rate of 28/min, 
oxygen saturation of 92%. Examination showed scleral 
icterus, tender hepatomegaly and a suppurative skin lesion, 
which had started ulcerating. Three weeks before 
presentation, the patient had sustained an injury on the 
dorsal aspect of his right foot while working in a shrimp 
factory. He did not seek any medical help at that time, but 
gradually developed fever over last 5 days and a pustule 
within the last 2 days. On close observation, the site 
around the lesion was swollen, tense, erythematous with a 
collection of pus, peeling of skin, sloughing off, presence 
of sinuses, and discharge of pus material. 
He was provisionally diagnosed with osteomyelitis of 
first metatarsal and started on Inj. ceftriaxone 2 gm/24 h, 
Inj. vancomycin 1 gm/8 h and oral metronidazole 400 mg 
bd. Hematological and blood chemistry results are 
represented in Tables 1 and 2. A pus sample drawn from 
the site was obtained, gram staining done and inoculated 
for culture on nutrient agar, blood agar and Mac Conkey 
agar and incubated overnight at 37°C. The next day 
numerous rounds, convex, butyrous colonies with a violet 
non diffusible pigment were obtained on all three media. 
Biochemically, it was identified as Chromobacterium 
violacuem (Table 3). 
Table 1: Results of blood tests for Case 1 
Blood tests Results Reference/level 
Haemoglobin (g/dl)  8.4 [11–14] 
Red cell count (cell/mm3) 3.3 million 4.0–5.5 million 
Platelets (cell/mm3) 275,000 150,000–
400,000 
White blood cell  
(cell/mm3) 
14,500 4000–11,000 
Neutrophils (%) 82 13–35 
MCV (fl) 82 78 ± 6 
MCH (pg) 30 27 ± 2 
MCHC (g/dl) 37 34 ± 2 
ESR (mm/hr) 120 10–15 
C-reactive protein (mg/dl) 21 <0.5 
MCV- Mean Corpuscular Volume, MCH- Mean 
Corpuscular Haemoglobin, MCHC- Mean Corpuscular 
HAemoglobin Concentration, ESR- Erythrocyte 
Sedimentation rate 
Antibiotic susceptibility testing was conducted by 
Kirby Bauer’s disc diffusion method in Mueller-Hinton 
agar according to CLSI guidelines for non-
Enterobacteriaceae [6]. The isolate was sensitive for 
amikacin, gentamicin, ciprofloxacin, meropenem, 
cefoperazone-sulbactam, cotrimoxazole, chloramphenicol 
and tetracycline. Ceftazidime and ceftriaxone were 
resistant for the isolate. Two days post admission with 
non-resolution of fever and ulceration, a second sample 
was sent for microbiological evaluation. Blood and urine 
samples for culture were unremarkable. On receipt of 
antimicrobial susceptibility report for the first sample, 
therapy was changed to Inj. cefoperazone-sulbactam 2 
gm/24 h and inj. metronidazole 15 mg/kg/6 h. 
Table 2: Blood chemistry results on admission (Case 1) 
Blood tests Results Reference/level 
Random blood sugar (mg/dl) 90 70–110 
Blood urea (mg/dl) 27 15–45 
Serum creatinine (mg/dl) 0.7 0.6–1.1 
Sodium (mEq/l) 139 135–146 
Potassium (mEq/l) 4.2 3.5–5.2 
SGOT (AST) (IU/l) 38 <40 
SGPT (ALT) ( IU/l) 43 <35 
ALP (IU/l) 185 90–460 
Abbreviations: ALT - alanine aminotransferase; ALP - 
alkaline phosphatase; AST - aspartate aminotransferase; 
SGOT - serum glutamic oxaloacetic transaminase; SGPT - 
serum glutamate pyruvate transaminase 
 The identification and antimicrobial sensitivities of 
2nd sample were similar to the 1st sample. However, after 
4 more days, a 3rd pus sample was sent after deterioration 
of his clinical condition with appearance of multiple 
discharging sinuses in right lower limb and the ulcer 
burrowing deep inside tissues with extensive sloughing. 
The patient was subjected to debridement of ulcer, necrotic 
material and sloughed off tissues were removed and the 
wound was washed with beta dine, hydrogen peroxide and 
normal saline (Fig. 1). C. violaceum was again isolated and 
identified, however cefoperazone-sulbactam turned 
resistant by now. A second blood sample sent for culture 
was also positive for C. violaceum infection. With the 
imminent danger of sepsis-induced mortality, therapy was 
re-evaluated and the patient put on Inj ciprofloxacin 400 
mg/8h and Inj. gentamicin 1.5 mg/8hy + Inj. clindamycin 
600 mg/6 h. The patient responded very quickly to this 
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regimen. Fever disappeared and the ulcer healed within 
next 10 days. He was discharged with oral ciprofloxacin 
500 mg BD for next 2 months. There was no evidence of 
recurrence after 6 months of evaluation. 
Table 3: Biochemical reactions of the isolate in Case 1 
Biochemical tests Results 
Gram stain Gram negative bacilli 
Catalase test Positive 
Oxidase test Positive 
Triple Sugar Iron agar Glucose fermenter, Lactose 
& Sucrose non fermenter, 




Urea hydrolysis test Negative 
Citrate utilization test Positive 
Methyl red test & Voges- 
Proskauer test 
Negative 
Hugh Leifson Oxidation 
Fermentation test 
Fermentative 
Lysine decarboxylase Negative 
Ornithine decarboxylase Negative 
Arginine dihydrolase Positive 
Pigment Violet (violacein) 





A 15-year-old male presented to the outpatient department 
of the hospital with complaints of burning micturition, 
pain abdomen, weakness, high grade continuous fever and 
chills, intermittent dysuria for 5 days. There was no history 
of any other concurrent illness. Abdominal examination 
revealed suprapubic tenderness. The patient was diagnosed 
with urinary tract infection and started on Inj. Cefotaxime 
1 gm/day. He divulged that a week ago, he had gone for 
catching fish with nets in a stagnant pond near his locality.  
 A routine urine wet mount showed >30 pus cells/ high 
power field with abundant bacteria and occasional granular 
casts. Lab investigations showed raised leucocyte count 
(>16,800 cells/mm3) with predominant neutrophilia 
(>85%) in an otherwise unremarkable routine 
hematological examination. 
 
Figure 1: Deep ulcerating lesion on dorsal aspect of 
right foot (case 1) 
A clean catch mid-stream urine sample was obtained, 
inoculated on CLED medium and incubated at 37°C 
overnight. Dark violet pigmented round, convex, regular 
colonies were observed in the culture plate the next day 
(Fig. 2). On identification, the gram negative motile bacilli 
were catalase positive, oxidase positive, fermented glucose 
with acid production but without gas. The bacteria utilized 
citrate, reduced nitrate, and were a lactose/sucrose non 
fermenter, showed fermentative character on Hugh Leifson 
medium, indole negative, urea hydrolysis negative, 
arginine dihydrolase positive and lysine, ornithine 
decarboxylase negative. The reactions were consistent 
with the identification of C. violaceum.  
 
Figure 2: Deep violet coloured colony in a blood agar plate 
(top half) 
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Figure 3 - Violet non diffusible pigment of 
Chromobacterium violaceum in a sensitivity plate 
Antimicrobial sensitivity testing was performed by 
Kirby Bauer’s disc diffusion method (Fig. 3). The isolate 
was sensitive to imipenem, cotrimoxazole, nitrofurantoin, 
ciprofloxacin, tetracycline, gentamicin, chloramphenicol 
and resistant to amoxiclav, cefepime, cefotaxime. A 
second sample sent on the alternate day was also identified 
as the same organism with the same sensitivity.  
The initial empiric therapy was revised and the patient 
put on Inj. Ciprofloxacin 400 mg bd followed 2 days later 
with oralCiprofloxacin 500 mg bd for 5 days. Blood 
samples sent for culture, on the pretext that such infections 
develop septicemia quite rapidly, were negative on two 
occasions. The patient recovered well within the next 
week. A 3rd urine culture examination 1 week after 
discharge did not find any bacteria present. He was 
continued on a regimen of cotrimoxazole over the next 2 
months to prevent relapse. Follow-up history was 
uneventful for next 6 months. 
DISCUSSION 
C. violaceum is a facultative anaerobe, motile gram 
negative bacillus producing a distinctive violet pigment. In 
spite of their ubiquitous distribution human infections are 
quite rare. Contrary to the widely regarded notion of them 
being nonpathogenic organisms, infections caused by them 
have the potential to trigger serious life threatening clinical 
conditions. C. violaceum infection is acquired mostly 
through the exposure of broken skin coming in contact 
with contaminated soil and water [7]. Severe infections 
after swimming in stagnant water, recreational theme parks 
or stagnant muddy water as well as post-surgical cases 
have also been reported. C. violaceum infection frequently 
presents with localized cutaneous infection followed by 
sepsis and multiple abscesses in the lungs, spleen, or liver 
with high mortality [3]. Orbital and periorbital cellulitis, 
osteomyelitis, urinary tract infection, pneumonia and 
meningitis are less frequently reported [8].  
The virulent strains of this bacterium have increased 
the levels of superoxide dismutase and catalase that 
protects this organism from phagocytic attack in humans 
[9]. Pigment production is not a predictor of virulence in 
the organism. Mortality rates are close to ~55%. Important 
risk factors for mortality include young age, neutrophil 
dysfunction, chronic granulomatous disease, presence of 
shorter clinical course and inappropriate antimicrobial 
therapy [3]. Septicaemia if set in, can be very fatal unless 
promptly treated [2]. In the first case described here, 
inappropriate antimicrobial therapy was responsible for 
septicaemia setting in. However, a prompt change in 
targeted therapy helped save the patient. 
Diagnosis of the condition requires microbiological 
confirmation by culture. The organism grows mostly on 
ordinary media with overnight incubation at 37°C. The 
presence of the spectacular deep violet pigment (violacein) 
is another clue for the identification of these bacteria. 
However, 9–11% of strains are nonpigmented and difficult 
to differentiate from organism like Aeromonas spp., 
Pseudomonas spp.,Vibrio spp., Flavobacterium spp. 
because of almost similar biochemical properties [7]. 
The organism is uniformly sensitive to 
fluoroquinolones, aminoglycosides, carbapenems, 
chloramphenicol, tetracycline, cotrimoxazole [10]. Genes 
associated with intrinsic resistance to penicillin, ampicillin 
and early cephalosporins have been described [11]. 
Alridge et al. found ciprofloxacin to be the most effective 
drug to treat C. violaceum infections [12]. A combination 
of a fluroquinolone with a amino glycoside/carbapenem 
has been found to be most successful therapy [3,12].  
However, it is noteworthy that several patients report 
relapse or recurrence of infections after successful 
completion of therapy for clinical cure [13]. It is possible 
for occult microabscess or hidden focus to persist in 
internal organs despite adequate clinical cure. Hence, it is 
prudent to treat patients for a longer duration and follow 
up patients closely to prevent relapse [3]. 
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CONCLUSION 
Though human infections with C. violaceum are rare, the 
consequences developed due to this infection can be highly 
fatal. Clinicians should consider C. violaceum infection for 
patients with a history of trauma and concomitant exposure 
of contaminated water. A high index of suspicion, prompt 
diagnosis, aggressive, targeted antimicrobial therapy and 
prolonged therapeutic duration is recommended for 
successful management C. violaceum infection. 
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